EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Discovery and development of Factor Xa inhibitors (2015–2022)

Wei Zheng, Xiaoqin Dai, Binyao Xu, Wei Tian, Jianyou Shi

Frontiers in Pharmacology · 21.02.2023 · 14

DOI: 10.3389/fphar.2023.1105880 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.02.2023. Verfasst von Wei Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT). And anticoagulant drugs are one of the most effective ways to prevent and treat these diseases. Although macromolecular anticoagulant drugs such as low molecular weight heparins (LMWHs) are widely used in the clinic, their characteristics of requiring injectable use hinder their further promotion in the clinic, and the disadvantages of oral anticoagulant drugs, such as warfarin and dabigatran etexilate, which can easily cause bleeding adverse effects, are also not addressed. Factor Xa (FXa) has gained attention because it lies at the intersection of the coagulation cascade pathways, whereas subsequently introduced Factor Xa inhibitors such as rivaroxaban and apixaban, among others, have gained market popularity because of their high potency for anticoagulation and high specificity for Factor Xa when administered orally. But some of the drawbacks that these Factor Xa inhibitors have simultaneously such as fewer indications and the lack of an effective reversal drug when bleeding occurs are urgently addressed. The development of new Factor Xa inhibitors therefore becomes one means of addressing these questions. This article summarizes the small molecule Factor Xainhibitors developed from 2015 to 2022, classifies them according to their scaffolds, focuses on the analysis of their structure-activity relationships, and provides a brief assessment of them.

Schlagwörter

Stichwörter der Autor:innen

FXaanticoagulant activitycoagulation cascadesmall molecule drug designstructure-activity relationship

Autor:innen und Institutionen

  • Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
  • Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and…
  • Department of Traditional Chinese Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, C…
  • Operations Management Department, Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu Sichuan China School of Medicine, University of Electronic Science…

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Natural Science Foundation of Sichuan Province
  • State Administration of Traditional Chinese Medicine of the People’s Republic of China

Zitieren

APA

Zheng, W., Dai, X., Xu, B., Tian, W., & Shi, J. (2023). Discovery and development of Factor Xa inhibitors (2015–2022). Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1105880

Vancouver

Zheng W, Dai X, Xu B, Tian W, Shi J. Discovery and development of Factor Xa inhibitors (2015–2022). Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1105880

BibTeX
@article{Zheng2023,
  author = {Zheng, Wei and Dai, Xiaoqin and Xu, Binyao and Tian, Wei and Shi, Jianyou},
  title = {Discovery and development of Factor Xa inhibitors (2015–2022)},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1105880}
}
Kostenlos starten →